Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience-Reference-Cited by-同舟云学术

Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience

Published:2015-04-20 Issue:3 Volume:170 Page:398-407
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Giona Fiorina¹,Putti Maria C.²,Micalizzi Concetta³,Menna Giuseppe⁴,Moleti Maria L.¹,Santoro Nicola⁵,Iaria Grazia⁶,Ladogana Saverio⁷,Burnelli Roberta⁸,Consarino Caterina⁹,Varotto Stefania²,Tucci Francesca⁴,Messina Chiara²,Nanni Mauro¹,Diverio Daniela¹,Biondi Andrea¹⁰,Pession Andrea¹¹,Locatelli Franco¹²¹³,Piciocchi Alfonso¹⁴,Gottardi Enrico¹⁵,Saglio Giuseppe¹⁵,Foà Robin¹

Affiliation:

1. Haematology; Department of Cellular Biotechnologies and Haematology; ‘Sapienza’ University; Rome Italy

2. Haemato-Oncology Unit; Department of Women's and Children's Health; University of Padua; Padua Italy

3. Clinical Experimental Haematology Unit; Gaslini Research Institute of Genoa; Genoa Italy

4. Paediatric Haematology Unit; Pausilipon Hospital; Naples Italy

5. Department of Paediatrics; Paediatric Unit ‘F. Vecchio’; University of Bari; Bari Italy

6. Division of Haematology; ‘Bianchi-Melacrino-Morelli’ Hospital; Reggio Calabria Italy

7. Department of Paediatrics; Haemato-Oncology Unit; ‘Casa Sollievo della Sofferenza’ Hospital; San Giovanni Rotondo Italy

8. Paediatric Haemato-Oncology Unit; Sant'Anna Hospital; Ferrara Italy

9. Haemato-Oncology Unit; Azienda Ospedaliera ‘Pugliese-Ciaccio’; Catanzaro Italy

10. Department of Paediatrics; University of Milano-Bicocca; Monza Italy

11. Haemato-Oncology Unit; Department of Paediatrics; University of Bologna; Bologna Italy

12. Department of Paediatrics; University of Pavia; Pavia Italy

13. Paediatric Haematology-Oncology; IRCCS Ospedale Paediatrico Bambino Gesù; Rome Italy

14. Biostatistics Unit; GIMEMA Foundation; Rome Italy

15. Department of Clinical and Biological Sciences; University of Turin at Orbassano; Turin Italy

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13453/fullpdf

Reference39 articles.

1. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet;Baccarani;Blood,2006

2. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet;Baccarani;Journal of Clinical Oncology,2009a

3. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study;Baccarani;Blood,2009b

4. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013;Baccarani;Blood,2013

5. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study;Baccarani;International Journal of Hematology,2014

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment and follow‐up of children with chronic myeloid leukaemia in chronic phase (CML‐CP) in the tyrosine kinase inhibitor (TKI) era—Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort;British Journal of Haematology;2023-12-14

2. The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study;Blood Advances;2023-12-01

3. Children with chronic myeloid leukaemia treated with front-line imatinib have a slower molecular response and comparable survival compared with adults: a multicenter experience in Taiwan;British Journal of Cancer;2023-01-30

4. Case Report of Renal Calculi in a Child Receiving Imatinib for Acute Lymphoblastic Leukemia;Canadian Journal of Kidney Health and Disease;2023-01

5. Principles of Monoclonal and Small Molecular Targeting Agents for Pediatric Cancer Management;Pediatric Surgical Oncology;2023